becotatugvedotin plus gemcitabine
Preclinical
becotatugvedotin plus gemcitabine is one of 6 therapeutic programs targeting Pancreatic Ductal Adenocarcinoma (PDAC). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Pancreatic Ductal Adenocarcinoma (PDAC)
#DrugCompanyPhaseTrials
1Fotivda
RochePhase 2
Erbitux
IImclone
Phase 2
[18f]fapi-74 Pet/ct
SSOFIE
Phase 3
VS-7375
VVerastem, Inc.
Phase 2
BT5528
BBicycleTx Limited
Phase 2
becotatugvedotin plus gemcitabine
PPeking Union Medical College Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]